Clinical Trials Logo

Locally Advanced clinical trials

View clinical trials related to Locally Advanced.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06120387 Recruiting - Locally Advanced Clinical Trials

Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Start date: November 10, 2023
Phase:
Study type: Observational

In this study, we propose to conduct an ambispective study to analyze the safety of preserved renal unit surgery combined with postoperative adjuvant radiotherapy in patients with limited stage ureteral cancer with high risk factors, and the efficacy analysis compared with traditional radical surgery. It is hoped that a treatment method that preserves patients' renal function to improve the tolerance of subsequent drug therapy without decreasing the effect of tumor treatment can be achieved in patients with high-risk factors.

NCT ID: NCT06020430 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Start date: February 8, 2024
Phase: N/A
Study type: Interventional

Radical radiotherapy is critical for locally advanced non small cell lung cancer(NSCLC ). Our previous sturdy indicated that patients who received induction immunotherapy and subsequent radiotherapy suffered higher proportion of pneumonitis.Grade 2 or more pneumonitis patients have worse prognosis. It is urged to optimize the radiotherapy dose and target volume for patients treated with immunotherapy and radiotherapy. According to retrospective and prospective studies, omitting CTV radiation is feasible for patients undergoing concurrent radio-chemotherapy for locally advanced NSCLC. It is postulated that omitting CTV radiation for patients responded to induction therapy with immunotherapy and chemotherapy will have less pneumonitis without sacrificing the local control rate. Omitting CTV may also retain better immune function which will facilitate the immunotherapy.

NCT ID: NCT05877573 Recruiting - Rectal Cancer Clinical Trials

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced,High-Risk,MSS Rectal Cancer

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This is a single arm, open-label, prospective clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and toripalimab (PD-1 antibody) for locally advanced rectal cancer (LARC) patients with high risk factors. A total of 53patients will be enrolled in this trial to receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody. Then they will receive the TME surgery and another 2 cycles of CAPOX chemotherapy. The primary end point is the rate of pathological complete response (pCR). The long-term prognosis and adverse effects will also be evaluated and analyzed.

NCT ID: NCT05802394 Recruiting - Pancreatic Cancer Clinical Trials

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer

MAP-03
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions it aims to answer are: - prognostic value of baseline MRD; - the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before conversion therapy initiation and at the first imaging assessment after chemotherapy.

NCT ID: NCT05766800 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Start date: March 14, 2023
Phase: Phase 2
Study type: Interventional

For unresectable locally-advanced non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial. However, it is unclear whether surgery can provide survival benefit for patients with tumors initially unresectable transformed into resectable ones after chemoimmunotherapy. This trial aims to investigate the efficacy and safety of the therapeutic regimen of chemoimmunotherapy plus surgery.

NCT ID: NCT05763641 Recruiting - Breast Cancer Clinical Trials

TAD After Chemotherapy in Locally Advanced Breast Cancer

Start date: February 1, 2021
Phase:
Study type: Observational [Patient Registry]

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

NCT ID: NCT05679674 Recruiting - Pancreas Cancer Clinical Trials

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Start date: September 21, 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use the TTF system for at least 18 hours per day starting on the first day of SABR until the tumor progresses or severe toxicity develops.

NCT ID: NCT04585750 Recruiting - Breast Cancer Clinical Trials

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Start date: October 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2 study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors containing a TP53 Y220C mutation.